10.1016/s1473-3099(13)70257-3 - Once-daily dolutegravir versus twice-...

This document has been corrected

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

10.1016/s1473-3099(13)70257-3

Published Online: 2013-11-?

Journal: The Lancet Infectious Diseases•Publisher: Elsevier BV

Authors: Clare Brennan•Elena Belonosova•Eugenia Quiros-Roldan•François Raffi•Hans Jaeger•Helmut Albrecht•Jean-Guy Baril•Jose M Gatell•Pere Domingo•Sherene Min•Steve Almond

This document has been corrected

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

10.1016/s1473-3099(13)70257-3

Published Online: 2013-11-?

Journal: The Lancet Infectious Diseases

Authors: Clare Brennan•Elena Belonosova•Eugenia Quiros-Roldan•François Raffi•Hans Jaeger•Helmut Albrecht•Jean-Guy Baril•Jose M Gatell•Pere Domingo•Sherene Min•Steve Almond

NOW

2014-08-01•Erratum

Corrections

10.1016/s1473-3099(14)70858-8

* information provided by CrossRef

2014-08-01•Erratum

10.1016/s1473-3099(14)70858-8

* information provided by CrossRef

2013-11-?•Published

This document has been corrected

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

10.1016/s1473-3099(13)70257-3

Published Online: 2013-11-?

Journal: The Lancet Infectious Diseases•Publisher: Elsevier BV

Authors: Clare Brennan•Elena Belonosova•Eugenia Quiros-Roldan•François Raffi•Hans Jaeger•Helmut Albrecht•Jean-Guy Baril•Jose M Gatell•Pere Domingo•Sherene Min•Steve Almond